J&J pauses manufacturing of its COVID-19 vaccine – NYT

Johnson & Johnson late final 12 months quietly shut down the one plant making usable batches of its COVID-19 vaccine, the New York Occasions reported, citing individuals conversant in the choice.

The halt is short-term, with the Leiden plant anticipated to start out making the vaccine once more after just a few months, the NYT report mentioned. The paper added it was not clear whether or not the pause has had an influence on vaccine provides but, due to stockpiles.

The corporate didn’t instantly reply to a Reuters request for remark.

The power, within the Dutch metropolis of Leiden, has as an alternative been making an experimental however probably extra worthwhile vaccine to guard in opposition to an unrelated virus, in line with the report.

The drugmaker final month forecast as a lot as $3.5 billion in gross sales of its COVID-19 vaccine in 2022, a 46% leap, having fared poorly in comparison with rivals.

The corporate reported gross sales of $2.39 billion for the COVID shot in 2021, lacking its personal goal of $2.5 billion, in a 12 months marked by manufacturing stumbles, security considerations and uneven demand for a vaccine as soon as touted as a promising instrument for inoculating populations in hard-to-reach areas.

With the Leiden plant quickly unavailable, it might cut back the availability of the J&J vaccine by just a few hundred million doses, the NYT report mentioned, citing one of many individuals conversant in the choice.

Different services have been employed to fabricate the vaccine however they’re both not up and operating but or haven’t acquired regulatory approval to make the shot, the report added.

See also  Weight problems might trigger melancholy even in absence of well being points